THISTORY Raises ￥100M in Series B Round

According to VCBeat, on September 2, 2020, Shenzhen Chuanshi Biomedical Co., Ltd ("THISTORY") announced the completion of a Series B financing of more than 100 million yuan, led by Sherpa Venture Capital with additional support from the existing investor Shenzhen Yuanzhi Fuhai Investment.

Founded in Shenzhen in 2017, THISTORY focuses on the diagnosis and prevention of cardiovascular and cerebrovascular diseases. The company is committed to creating an innovation-driven and global-oriented medical device brand. 

With strong innovation strength in biological research, the "Yan Xing" series of coagulation analysis products independently developed by THISTORY has integrated the two major methods of coagulation test for the first time, breaking the status of product R&D in the subdivided industry, and becoming the pioneer in the field of coagulation analysis. 

Among them, the performance of YX ("Yan Xing") -3000 has reached the international top level for its precision, speed and reliability. At present, the product has been launched to the market.

Dr. Zhang Huali, general manager of THISTORY, said that proceeds from the latest round will be used for systematic construction in the market and sales channel, and the launch of "Yan Xing" series products to meet the needs of clients at different levels.

Founded in 2018 and is headquartered in Beijing, China, Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where the company has established robust portfolio sources, lasting value-adding cooperation and relationships, as well as mature all-cycle services with key resources.

Shenzhen Yuanzhi Fuhai Investment is a large fund company of M&A jointly established by Shenzhen State-owned Assets Supervision and Administration Commission, Oriental Fortune Capital, and others. It was established in Qianhai, Shenzhen in February 2013. The company focuses on M&A in strategic emerging industries. Its management team has more than 10 years of practical experience in equity investment and M&A.